miR-600 inhibits lung cancer via downregulating the expression of METTL3
Authors Wei W, Huo B, Shi X
Received 21 July 2018
Accepted for publication 21 December 2018
Published 1 February 2019 Volume 2019:11 Pages 1177—1187
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 1
Editor who approved publication: Dr Rituraj Purohit
Wenwen Wei,1,* Baosheng Huo,2,* Xiulan Shi1
1Department of Respiratory Medicine, The Second People’s Hospital of Dongying, Guangrao City, Shandong Province 257335, People’s Republic of China; 2Department of Thoracic Surgery, The Second People’s Hospital of Dongying, Guangrao City, Shandong Province 257335, People’s Republic of China
*These authors contributed equally to this work
Background: Methyltransferase like 3 (METTL3) is an RNA methyltransferase implicated in mRNA biogenesis, decay, and translation control through N6-methyladenosine (m6A) modification.
Methods: To find new treatment strategies for lung cancer and to elucidate the mechanism underlying the phenomenon, we treated the human lung cancer cell lines A549 and H1299 to investigate the effect of METTL3 on lung cancer.
Results: We observed that knockdown of METTL3 inhibited the survival and proliferation of A549 and H1299 cells. The migration and proliferation of both cell lines were significantly decreased, and the apoptosis was induced in comparison with control cells. These results were further confirmed by the transfection of miRNA of METTL3 increased the Bax/Bcl-2 ratio in A549 and H1299 cells, which is a sign that mitochondrial apoptotic pathway was triggered. The PI3K/Akt pathway is implicated in cell growth and survival and we also observed that knockdown of METTL3 changed the expression and phosphorylation of proteins of PI3K signaling pathway members. Further, our results demonstrated that miR-600 inhibited the expression of METTL3 and reversed the positive effect of METTL3 on NSCLC progression, indicating an miR-600/METTL3 pathway in NSCLC.
Conclusion: These data suggested that miR-600 inhibited lung cancer via down-regulating METTL3 expression, and knockdown of METTL3 might be used as a novel strategy for lung cancer therapy.
Keywords: METTL3, miRNA, lung cancer, A549, H1299, apoptosis, PI3K pathway
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]